Catalyst Biosciences (CBIO) Prices 4.6M Shares at $6.50

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about February 18, 2020, subject to customary closing conditions.

The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. This amount assumes no exercise of the underwriters’ option.

The Company anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical and manufacturing activities for Marzeptacog alfa and dalcinonacog alfa, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.

Raymond James & Associates, Inc. is acting as the sole book-running manager and JonesTrading Institutional Services LLC, Chardan and LifeSci Capital LLC are acting as co-managers for the offering.

You May Also Be Interested In

• Raymond James on Whirlpool Corporation (WHR): 'July Major Appliance Industrial Production Remained Weak'
• Aveanna Healthcare prices secondary offering at $11.75 per share
• QNB Corp. overallotment option adds 160,714 shares at $42 each